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Abstract--The multinational biopharmaceutical industry has to 
deal with significant financial pressures due to being a very cost-
constrained and highly regulated industry. To add to that, finite 
patent expirations on financially successful drugs, vying nature of 
the biotech industry due to new innovations. There has been an 
increase of smaller markets due to the proliferation of molecular 
segmentation patient populations in fields such as personalized 
medicine. Particularly, due to the significant cost reducing impacts 
of the development of “next-generation” sequence platforms on 
DNA sequencing in the last decade, molecular diagnostics are 
being considered as cost effective candidates to be used as a 
standard medical test, in terms of risk assessment, confirmation of 
diseases, and therapeutics. Biopharmaceutical companies need to 
reassess their drug development strategies and choose among 
alternative prospective business models in order to remain 
relevant amid the new innovations and developments. Using a 
dynamic capabilities lens, this paper tends to study the impact of 
genomics generally and gene therapy specifically on the rare 
disease sector of the biopharmaceutical industry by analyzing the 
public data from 24 genomics based rare disease focused 
biopharmaceutical companies. This study shows that growing 
rates of cumulative returns is dependent upon the accumulation of 
knowledge-based employees and expanding product portfolios of 
disruptive genomics-based technologies for treating rare diseases. 
Further, this study stresses the significance of structuring the 
capability and capacity to absorb expertise and accrue knowledge 
for new product innovations and viable competitive advantage. 
I. INTRODUCTION 
Multinational biopharmaceutical firms exist in an 
increasingly cost-constrained and highly regulated ecosystem. 
Concurrently, these companies have to cope with constant 
competitions which is imposed upon them due to their 
blockbuster drugs’ expirations followed by the imminent 
emergence of generic drugs. They also exist in an environment 
which possesses a very high innovation rate and companies can 
lose their market monopoly due to new disruptive technologies. 
Moreover, in the last decade, there has be an escalation in the 
number of smaller markets due to the fall in the cost of DNA 
sequencing in result of  the development of “next-generation” 
platforms and increase in genetic segmentation of patient 
populations. Molecular diagnostics in particular are now being 
considered as cost effective standard medical test options for 
assessing risk and diseases confirmations—and increasingly, as 
therapeutics for rare diseases as a result of DNA sequencing’s 
affordability. Because of all these changes, it is imperative for 
biopharmaceutical companies to reassess their drug 
developments strategies and business models in order to stay 
relevant and competitive in this unforgiving market. 
In the recent years there has been a paradigm shift in big 
multinational pharmaceutical companies’ models. Companies 
like Merck, Pfizer, Roche, and Glaxo are no longer dismissing 
the rare disease market due to its small addressable market and 
targeted population. In contrast to the past, they are more 
interested in investing in rare disease treatments. Even some 
health systems are now focusing more on the importance of 
genetic predispositions and genomics related data as part of 
invigorating e delivery of care to the patients [1]. 
Currently, about 10% of Americans are dealing with 
approximately 7,000 rare diseases (only 5% with approved 
treatments) [2, 3]. Among a significant amount of technological 
breakthroughs in the recent years, one that has undoubtedly 
influenced the mentioned economic paradigm shift is the DNA 
sequencing which is the mapping of the human genome. The 
introduction of Sanger-based advances has caused the cost of 
sequencing a human-sized genome to plummet substantially 
from $100 million to $1,000 in the last three decades [4, 5]. This 
new technology would mean substantially less amount of time 
needed for patient testing, higher government financial 
incentives, pediatric review voucher, and more approval rates 
from US Food and Drug Administration [6]. 
The genomics revolution is expected to disrupt traditional 
multinational pharmaceutical industry structure. In other words 
the sole focus is not going to be relying on large, chronic drug 
blockbusters targeted at large patient populations. Disruptive 
innovations such as gene therapy can deliver single treatment 
cures and can potentially shift the status quo in the 
biopharmaceutical industry structure. Amid these changes, 
biopharmaceutical companies are in great need to reprioritize 
drug development strategies and carefully choose among future 
business models options in order to stay competitive in a high-
velocity market such as the biopharmaceutical industry. Using 
a dynamic capabilities lens, this proceeding aims to study the 
impacts of different financial, organizational, and product-
related resources on the enterprise value of genomics-based rare 
disease-focused biopharmaceutical companies. In order to 
pinpoint the influence of decreased cost and increased attraction 
in genomics generally and gene therapies specifically (delivery 
of single treatment cure using corrective genes for fatal rare-
diseases) on biopharmaceutical companies, the industry 
background and the influence of genomics in rare diseases are 
briefly studied. This study delves into capability and capacity 
building rare disease-focused biopharma companies. 





Figure 1. Cost per genome evolution compared to hypothetical data reflecting 
Moore’s Law [5] 
 
II. THE BIOPHARMA INDUSTRY 
The biopharmaceutical industry is a mixture of traditional 
multinational drug manufacturers, biotechnology companies, 
and distribution companies mainly focused on medicinal and 
veterinary chemical and biological combinations. A 
pharmaceutical firm can be defined as company that performs 
commercial R&D, marketing, and distribution of drugs [7]. 
Biotechnology is defined as techniques for changing 
microorganisms, and a biotechnology company focuses on 
manipulating living cells (plants or animals) using biological 
knowledge [8]. Pharmaceuticals and biotechnology 
organizations are placed in a highly dynamic industries with 
intense global competition, new product development (NPD) 
plays a significant role in reaching success in these types of 
companies [9]. Therefore, drug development companies have 
been shifting their strategies from manipulating natural 
compounds to use of new biologic understanding and tools in 
order to come up with new drug ideas and bolster their pipelines 
[10, 11].  
New genomic insights and tools such as gene therapy, 
regenerative medicine and molecular diagnostics are causing 
significant industry paradigm shift from active disease 
confirmation to treatment decision-making, avoidance and 
wellness [12]. As one of the largest employers of scientists and 
one of the highest levels of R&D among industries (increasing 
R&D expenditure from $2.0 billion in 1980 to $51.4 billion in 
2014 in US), the pharmaceuticals industry targets large global 
markets [11, 13]. As an example, the United States possesses 
86% of global biotech financing [14]. Some of the other traits 
of the biopharmaceutical industry are lengthy drug 
development wait times (10-12 years), low levels of successful 
drug transformation from clinical trials to approved drugs (less 
than 12%), high drug development costs (from $179 million in 
1970s to $2.6 billion in 2000s-early 2010s), and high R&D 
expenditure as fractions of sales (23.4% and 17.9% for domestic 
and total sales respectively) [15, 16]. An Ernest & Young 
(2016) noted that 78 biotech companies offered their initial 
public offerings and raised $5.2 billion in their IPOs, of which 
45 were from US. Multinational biopharmaceutical companies 
are stressing the significance of strategic alliances in bolstering 
their pipelines (Ahn, et al., 2009; 2010).  
One of the more disruptive sub-sectors of the 
biopharmaceutical industry is genomics which has an impact on 
different parts of the industry. An example of this are the 
companies that concentrate on single treatments for rare 
diseases. Therefore, many companies are significantly 
increasing R&D investment in genomics to penetrate the rare 
diseases market and take advantage of the new opportunities in 
treating unmet medical needs. 
A. Genomics in Rare Disease Treatment? 
Genomics is the scientific discipline of sequencing, mapping, 
and characterization of human genes. This breakthrough has 
had a significant impact on drug discovery and development in 
the biopharmaceutical industry [17, 18]. Molecular genetics has 
significantly advanced drug development from risk assessment, 
early detection, and targeted therapies for needed medical 
shortages [19].  
In the last 20 years, the cost of sequencing a human-sized 
genome has descended substantially from $100 million to about 
$1,000. Sequencing industry leader Illumina is aiming for a 
$100 genome while focusing on accurate next generation 
sequencing (NGS) solutions, sequencing systems, and data 
analysis. The accelerated change of speed and the fall of per 
genome cost in the last decade reflects the shift from Sanger-
based sequencing to next-generation genome sequencing 
technologies [4]. The rise of NGS technologies has enabled the 
generation of an enormous volume of data in a way more 
reasonable way (up to 1 billion short reads per instrument run) 
[20]. The information that genomics provides has the ability to 
improve our understanding of disease biology, personalized 
therapies and ,in result, better health decision making through 
their combination with new technologies [21, 22]. 
The treatment of rare disease has been one of the biggest 
and most disruptive opportunities for the progress in genomics. 
Rare diseases provide researchers with smaller patient 
populations, and can enable the cost effective development of 
drugs for a non-homogeneous spectrum of diseases within a 
specific genetic disorder [23]. Rare disease is defined by the 
Rare Disease Act of 2002 as "any disease or condition that 
affects fewer than 200,000 people in the US” [24]. Genomics is 
facilitating researchers in better understanding the nature, 
severity, rate of progression, and clinical presentation of these 
diseases, many of which have impacts on pediatric populations. 
In a more pragmatic way for smaller biopharma companies, the 
increased interest in rare diseases is also provoked by smaller 
clinical trial populations, increased government financial 
incentives, and higher approval rates from US Food and Drug 
Administration (FDA). FDA Commissioner Scott Gottlieb 
noted that: “new guidance on the clinical evaluation of targeted 
therapies for rare disease subsets by the FDA…will address the 
issue of targeted drugs, and how we simplify the development 




















































variations, and where diseases will all have a similar genetic 
fingerprint” [25]. 
As an example, Avexis, Inc. is developing AVXS-101 
(gene therapy) for the treatment of Spinal Muscular Atrophy 
(SMA), which is uniformly fatal by 2 years of age [26]. This 
disease is caused by a single genetic defect and Avexis has the 
goal of alleviating or treating this disorder with the help of 
single treatment gene therapy. Initial results presented in 2017 
demonstrated that 15 of 15 (100%) patients were event-free at 
13.6 months (versus an expected event-free survival rate based 
on the natural history of the disease of 25%). Many companies 
such as Avexis, Biomarin, Bluebird, Abeona, Dimension, and 
Spark are targeting different debilitating, genetically-based rare 
diseases. 
Many biotech firms embark on strategic alliances with 
larger firms to take advantage of the resources and attain 
validation [27]. Bluebird bio’s partnership with Celgene; or 
Spark Therapeutics partnership with Pfizer in the development 
of SPK-9001 drug for the treatment of Hemophilia B are 
examples of this organizational behavior [28]. Moreover, some 
of these rare disease-focused biotech companies are co-located 
in biotech clusters such as New England and California which 
account for 17 of the 24 studied companies. Biotech clusters 
enhance access to academic research centers, qualified 
employees, experienced vendors and suppliers, informed life 
science venture investors, and shared resource arrangements 
[29, 30, 11, 31].  
Ultimately, industry sectors rise by creating, building and 
capturing value. While the biotech sector has dramatically 
outperformed the S&P 500 index (which represents the US 
stock market index based on the market capitalizations of 500 
large companies having common stock listed on the NYSE or 
NASDAQ), the Rare Disease sub-sector of the biotech market 
has experienced extraordinary growth (Figure 2). 
 
Figure 2: Stock Market Performance: S&P 500 
vs. Biotechnology v Rare Disease Companies 
In conclusion, biopharmaceutical companies need to acquire 
dynamic capabilities in order to recognize, assimilate, 
transform, and exploit their tangible and intangible assets (tacit 
knowledge, R&D know-how, NPD, alliances and acquisitions, 
and skilled workforce attraction) in order to accelerate 
innovation [32, 33]. Markets such as biopharmaceuticals are 
finely tuned to recognize and assess value, assess and manage 
risks and reward companies who innovate in targeted therapies 
[34, 31]. The reason this study considers 24 companies is that 
there are currently 24 rare-disease focused, and genomics-based 
companies in the United States. 
III. DYNAMIC CAPABILITIES 
In the new technology-based era of NPD, faster information 
flow, and easier and faster access to markets, managing and 
orchestrating intangible assets are vital to building unique value 
and competitive advantage [35]. Teece, Pisano & Shuen [36] 
suggest that competitive advantage is built and protected not in 
product markets but in markets for know-how and other 
intangibles which they refer to as the dynamic capabilities.  
There are multiple definitions of dynamic capabilities in the 
literature. Pisano [37] defines them as organizational and 
strategic routines that allow managers to change, jettison, 
integrate, and re-connect resources in order to create new value-
generating blueprints [38]. Dynamic capabilities are tools for 
generating, evolving, and morphing of resources to attain 
sustainable competitive advantage [36, 39]. By merging these 
definitions, [40] defines dynamic capabilities as the company’s 
organizational and strategic actions to use, integrate, 
recombine, acquire and dispose of resources to equal or 
generate market change as a response to emergence, evolution, 
division, and demise of markets [41]. Some of these actions can 
be alliances, acquisitions, NPD, and strategic decision-making 
[42].  
Moreover, Eisenhardt and Jeffrey [41] discuss multiple 
common characteristics between dynamic capabilities across 
high-tech organizations. Despite the fact that dynamic 
capabilities differ across various firms, some traits such as 
being “equi-final” (reaching dynamic capabilities from 
different roads and being path dependent); “compatible” 
(effectiveness of some capabilities across different industries); 
and “dependent on market animation and learning methods” can 
be common among technology-based companies [43, 41, 44]. 
In the context of the high velocity genomics-based 
biopharmaceutical markets, dynamic capabilities are dependent 
on the generation of new knowledge for increasingly specific 
patient populations. Moreover, firms with dynamic capabilities 
employ unique types of adaptive knowledge which can create 
activities as real-time information, prototyping, multi-criteria 
decision-making, and experimenting in an iterative and 
cognitive way, which leads to unpredictable outcomes [41].  
Biopharmaceutical companies must adapt to fast-changing 
markets and rapid learning processes [45]. This environment 
necessitates the significance of learning from experience in 
order to create dynamic capabilities [46]. Studies demonstrate 
that the learning mechanism, rather than detailed a priori plans, 
plays an important part of the evolution of dynamic capabilities 
for firms. Repeated practices (in activities such as acquisitions, 
integration, and getting rid of resources) which lead to crucial 
gain of specific and tacit knowledge for firms [47, 48, 49]. What 
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to systemize, articulate, share, and embed the acquired 
knowledge into procedures and know-how as a way to a faster 
organizational learning [48, 41, 65, 58]. Managers must acquire 
information from mistakes, failures and crises (real time and/or 
simulated scenarios) [50, 40, 51]. 
Experience and speed can also improve the creation of 
dynamic capabilities through rapid acquisition of experience 
that can strengthen managers’ decision-making ability, improve 
knowledge, and hone insights [48, 41]. Accumulation of 
experience in the selection and jettison of the products and 
businesses based on distinctive market changes is another 
important parts of dynamic capabilities vital for firms [46, 52]. 
Lastly, sequence appears to be important in generating dynamic 
capabilities [49, 41]. By assuming that dynamic capabilities as 
being modular and composed of smaller components 
(ingredients), the order of composition and implementation of 
smaller modules into a dynamic capability (recipe) is crucial for 
firms. 
More recently, Pisano describes firm’s capability problem 
as a problem being about selecting between different 
identification strategies for needed kind of capabilities. Each 
firm has to choose to either go deep or broad, general or market 
specific in terms of dynamic capabilities [53]. 
In sum, competitive advantage in high tech environments 
such as biopharmaceuticals is often episodic, fleeting and 
erratic. Hence, continual acquisition and rethinking of 
intangible assets and resources (sensing, seizing, and 
transforming) in order to generate and manage dynamic 
capabilities is vital to firms’ success.  
IV. DATA COLLECTION AND METHODOLOGY 
As the next step, by considering the disruptive biopharma 
sub-sector of rare disease being directed by breakthroughs in 
genomics, we used the Biocentury database which tracks over 
1,300 public and 4,000 private biotech companies worldwide 
from 1995-present with goal of finding  elements of dynamic 
capabilities in building, creating and capturing value in the 
studied companies. We identified 24 publicly-traded rare 
disease-focused biotech companies, 18 of which focus 
exclusively on gene therapy, during the 1995-2017 period [25]. 
In the United States, a rare disease is defined as one that affects 
fewer than 200,000 people. According to the Genetic and Rare 
Diseases Information Center (GARD) at the National Institutes 
of Health, there are over 7,000 rare diseases with less than five 
percent having an approved treatment. The studied companies 
are primarily concentrated in biotech clusters located in 
Massachusetts and California (Figure 3).  
Data were collected for each company in 11 categories 
(revenue, enterprise value, net income, retained earnings/ total 
financing, cash, number of employees, CEO tenure, number of 
board of director members, year of foundation, year of IPO, 
clinical/commercial products, and number of total products) on 
May 5th, 2017. The definition for each of these criteria is shown 




Figure 3. Geographical Locations of Rare Disease-based Companies 
Where market capitalization is the total value of a 
company’s balance sheet and total cash is the sum of all the cash 
that a firm has in its books [54]. Descriptive statistics for the 
collected 24 companies are shown in Table 1. 
TABLE 1: DESCRIPTIVE STATISTICS FOR THE STUDIED COMPANIES 
 
The drug development process is lengthy and risky, with 
development times of 7.5 to 19 years [55]. To determine the 
status of each company in terms of NPD, data from their drug 
pipelines were collected for discovery, preclinical, Phase 1-3, 
and commercialization. The feasibility, iterative testing, and 
safety-related information are collected during preclinical 
development. In the first phase of clinical trials new drug 
products or treatments are examined on a small number of 
subjects to assess safety and dosage. The second phase involves 
further evaluation of a drug’s safety and efficacy by being tested 





on a larger population. In the third phase, the drug’s 
effectiveness, side effects, and safety is examined on a larger, 
statistically significant group of patients versus an active 
control (e.g., placebo or current standard of care).  
Each of these variables that are included in our statistical 
analysis fall under one of the three asset criteria. These criteria 
are finance-related, organizational related, and product related. 
The sub-criteria of each of these asset types can is shown in 
Table 3.  
In order to assess the relationships between the enterprises 
value of the studied firms with these financial, organizational, 
and product attributes in the disruptive biopharma sub-sector of 
rare diseases, this study uses a multi-variate regression analysis. 





TABLE 3. ASSET TYPES IN THIS STUDY 
Type of Asset Sub-Criteria 
Finance Assets Revenue, net income, cash and retained earnings 
Organizational Assets 
Number of employees, CEO tenure, and 
number of the board of directors’ 
members, year of foundation, and year of 
IPO 
Product Assets Number of products in various stages of development 
 
The dependent variable ‘Enterprise Value’ is analyzed with 
regards to independent variables with respect to correlation (r), 
p-value (p), and R-squared (R2). Correlation is the degree which 
two metric variables are related in a linear manner. In this case, 
(0 to (-) 0.3 is considered as weak correlation; (-) 0.3 to (-) 0.5 
is considered medium correlation; and (-) 0.5 to (-) 1.0 is 
considered as strong correlation. Negative correlations mean 
that an increase or decrease in the independent variable would 
result in the decrease or increase in the dependent value. The p-
value shows the significance (p <0.05) of the hypothesis. This 
means that if the p-value for each of the tests is >0.05 we reject 
the hypothesis (with 95% confidence). However, if the p-value 
is <0.05, we accept the hypothesis and consider the underlying 
assertion valid. Also, R2 refers to the percentage of ‘Enterprise 
Value (EV)’ that can be explained by different independent 
variables. In other words, R2 determines the proportion of the 
variance in EV that can be predicted using the tested 
independent variable. Finally, the non-standardized coefficient 
shows the amount of unit changes in the “Enterprise Value” 
with respect to changes in each independent variable. The 
results of regression tests and scatter plots are discussed next. 
As initial step, the linear relationship between the 
independent variable (EV) and the dependent variables should 
be checked. For this purpose, scatter plots are used to determine 
if there is a good linear relationship between EV and different 
independent variables. Based on the linear R-square values, 
only the variables with medium or high ability to explain the 
variability of the response data around their mean were selected 
(Figure 4).  As a result, revenue, retained earnings, number of 
employees, and total number of products were chosen for 
consideration. Cash was omitted from the analysis despite its 
higher R-square value due to the fact that it is a part of EV 
formula in order to avoid redundancy. Multivariate regression 
analysis (95% confidence) was applied to the selected four 
criteria in order to study their potential effects on the EV of 24 




Figure 4: Scatter Plots for Independent Variables against EV 
V. RESULTS & DISCUSSION 
The descriptive statistics for the variables that were analyzed 
with regards to their R-squared values in the previous step can 
be seen in Table 4. The results in Table 5 indicate that 
‘Revenue’, ‘Number of Employees’, and ‘Total Number of 
Products’ have predictive power of ‘Enterprise Value’ for the 
studied rare disease companies. The four selected independent 
values account for explaining about 96% (adjusted R-square) 
percent of EV value variances for the studied companies (Table 
7). In this section, the adjusted R-square has been used in order 
to reflect the number of predictors in the model. The decrease 
in the adjusted R-square compared to the R-square shows that 
the predictor improves the model by less than expected by 
chance. The standardized coefficients in Table 5 also highlight 
the impact of number of employees on EV as the highest 
predictor. 
Furthermore, number of employees and revenue were found 
to have significant correlations with the Enterprise Value at 
96% and 91% respectively. Among the three variables that had 
significant p-values regarding EV, number of products was the 
third correlated variable at 55% (Table 6). 
Table 8 shows the F-test with the null hypothesis that the 
model explains zero variance in the EV (H0: R2=0). As the result 
of the F-test is highly significant, we reject the null hypothesis 
and can conclude that the model explains a significant amount 
of the variance in the studied companies’ EV. 
TABLE 4. DESCRIPTIVE STATISTICS FOR ANALYZED VARIABLES 
Descriptive Statistics 
Mean Std. Deviation N 
EV $2,751.68 $6,199.315 24 
Revenue $262.02 $669.037 24 
Retained Earnings -$277.46 $538.745 24 
Employees 400.5000 712.92520 24 
Total Products 8.7083 5.47309 24 





95.0% Conf. Interval 
for B 
Beta LB UB 
(Constant) 0.84 0.40 -670.70 1576.65 
Revenue 0.21 2.34 0.03 0.21 3.84 
Retained 
Earnings 0.07 1.18 0.25 -0.68 2.46 
Employees 0.78 7.95 0.00 5.02 8.61 
Total 
Products -0.07 -1.21 0.04 -224.36 59.38 
a. Dependent Variable: EV 
TABLE 6. CORRELATIONS 
Correlations 









n EV 1.00 0.91 0.73 0.96 0.55 
Rev 0.91 1.00 0.80 0.83 0.37 
Ret. Earn 0.73 0.80 1.00 0.62 0.15 
Employee 0.96 0.83 0.62 1.00 0.68 
Tot. Prod 0.55 0.37 0.15 0.68 1.00 
 
TABLE 7. MODEL SUMMARY 






1 .987a 0.974 0.968 $1,103.45 
a. Predictors: (Constant), Total Products, Retained Earnings, Revenue, 
Employees 





TABLE 8. ANOVA 
 ANOVA 
 Sum of Sq df Mean Sq F Sig. 
Regressio
n 860790145.29 4 215197536 176.73 .000b 
Residual 23134548.15 19 1217607  
Total 883924693.45 23   
a. Dependent Variable: EV 




Finally, the normality of the residuals were checked with 
a normal P-P plot in order to make sure that the points 
generally follow the normal line without any strong 
deviations. Figure 5 indicates that the residuals are normally 
distributed. The results were also checked for multi-
collinearity in the multi-variate regression model and all 
included independent variables were in the acceptable ranges 
(as shown in table 9) in terms of tolerance (above 0.1) and 
variance inflation factor (below 10). This shows that there is 
correlation between predictors (revenue, number of 
employees, retained earnings, and number of products). 
 
Figure 5. Normal P-P Plot of Regression Standardized Residual 
TABLE 9.COLLINEARITY STATISTICS 
  Collinearity Statistics 
  Tolerance VIF 
Revenue 0.157 6.351 
Retained Earnings 0.322 3.103 
Employees 0.142 7.066 
Total Products 0.385 2.600 
 
 
To conclude, the enterprise values in the rare disease 
focused, genomics based companies that were studied is 
correlated with number of employees, their revenues, and the 
number of products in the portfolios. These results can re-stress 
the importance of tangible and intangible assets and capabilities 
such as employee knowledge (tacit and explicit) and new 
product development which both have been identified as 
dynamic capabilities in the literature [56, 57, 9, 44, 41, 58]. 
VI. CONCLUSION 
Biopharma companies have to constantly deal with intense 
financial, competitive, regulative, technological, and market 
fluctuation pressures. Amid the high change rates, competitive 
advantage can be evasive and short-lived. Therefore, it is 
imperative for companies to constantly morph and manage their 
tangible and intangible assets and resources (i.e., sensing, 
seizing, transforming) in order to be successful and/or survive. 
Multiple examples of dynamic capabilities in technology-based 
firms stress the need to respond to market price changes, 
acquisition/forming alliances with goals of asset and 
organizational reconfiguration, product innovation for 
organizational renewal, and resource divestment [59, 60, 61, 62, 
63].  
In order to earn these capabilities and add value, it is crucial 
for high-tech companies to attract expertise (i.e., employees in 
different levels of the organization such as researchers and 
board of director members) in order to guide company towards 
competitive advantage and commercial success. Furthermore, 
the aggregation of skilled and innovative employees lead to new 
product innovation and lead companies into a more flexible and 
efficient product pipeline. The knowledge and experience that 
the workforce can bring can be seen as a cumulative bolstering 
factor in leveraging dynamic capabilities which can be 
recognized, understood, and transformed in order to align with 
company goals and commercial success (i.e., increasing returns 
in enterprise value). In other words, technology managers’ duty 
does not end on managing the finance-related criteria of the 
technology. Their duty also encapsulate management of human 
resources, asset configuration, and strategic alliances efficiently 
towards higher velocity and more efficient innovation. Strong 
dynamic capabilities can be formed with the accumulation of 
experience, articulation and codification of knowledge, and an 
adaptive ability to change the way they solve problems as the 
environment transforms [64]. In the case of biopharmaceutical 
companies, more efficient, prolific, and flexible employees can 
guide company to more successful NPD and a more efficient 
R&D pipeline. 
The disruptive genomics transformation equips rare disease-
based biopharmaceutical companies with the opportunity to 
generate great value and shift the entire global industry from 
mass market to personalized medicine. Taking advantage of 
genomics and new technologies can direct biopharma firms to 
improve product innovation and boost their chances of 
attracting employee expertise, insightful boards of directors, 
and management teams. Biopharma managers should be alert in 
sensing the opportunities, threats, and resources followed by 
 
 
seizing and reconfiguring the acquired knowledge to fit their 
organization in order to gain and sustain competitive 
advantages. 
In this study, twenty-four rare disease-focused biopharma 
companies were studied and several variables were tested with 
respect to enterprise value. The companies were analyzed as a 
group of rare disease firms. We found that variables such as 
number of employees, revenue, and number of products are 
correlated (in that order) with the enterprise value in rare 
disease-focused biopharma companies.  
As an extension of this study, we would suggest comparing 
these results against the entire biotechnology industry as whole 
to better differentiate specialized rare disease companies. 
Furthermore, these variables can be analyzed based on the size 
of the companies (small, medium, and large cap). Individual 
linear regression can be implemented in order to take a deeper 
look into the relations of different variables compared to EV. 
Moreover, as number of employees was shown to be crucial to 
the EV values of the studied companies, further study into what 
kind of employees would have the most significant impact on 
biopharma companies might be insightful. Also, more research 
into the effects of the biopharma geographical clusters is 
intriguing as there is a definite geographical impact in terms of 
knowledge transfer and cross-pollination between firms in high 
velocity technological industries (as these areas employ more 
skilled employees and therefore accumulate more knowledge 
and enterprise value (shown as darker colored states) as shown 
in Figure 6).   
 
Figure 6. Active Geographical Clusters for Rare-disease Biopharma 
Companies and Respective Number of Employees 
Using a dynamic capabilities lens, this paper studied the 
influence of genomics generally and gene therapy specifically 
on the rare disease sector of the biopharmaceutical industry. 
This study found that increasing rates of cumulative returns 
depends on accumulating knowledge-based employees and 
expanding product portfolios of disruptive genomics-based 
technologies for treating rare diseases. Also, this study stresses 
the significance of constructing the capability and capacity to 
attract expertise and accrue know-how for new product 
innovations and viable competitive advantage. The findings of 
this paper highlight the influence of decreased cost and 
increased attraction in prospective prevalence of genomics and 
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